Skip to main content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis

  • 1,
  • 2,
  • 1,
  • 1,
  • 1, 3,
  • 1, 3,
  • 1,
  • 1, 3,
  • 1,
  • 1,
  • 1, 3 and
  • 1, 3Email authorView ORCID ID profile
BMC GastroenterologyBMC series – open, inclusive and trusted201717:110

https://doi.org/10.1186/s12876-017-0669-7

©  The Author(s). 2017

  • Received: 17 July 2017
  • Accepted: 15 October 2017
  • Published:
Open Peer Review reports

Abstract

Background

We aimed to evaluate the role of fecal calprotectin (FC) as a noninvasive marker for the disease activity of ulcerative colitis (UC) in a Korean cohort.

Methods

A total of 181 fecal samples were collected from 181 consecutive UC patients between April 2015 and September 2016. FC levels were measured using the Quantum Blue® Calprotectin rapid test. The laboratory test results, partial Mayo Score (pMS), and colonoscopic imaging findings at FC level measurement were retrospectively reviewed. The Mayo endoscopic subscore (MES) and UC endoscopic index of severity (UCEIS) were graded by 2 certified endoscopists after training with 50 other cases.

Results

The FC levels were significantly correlated with pMS (Spearman correlation coefficient r = 0.428, p < 0.001), MES (r = 0.304, p < 0.001), UCEIS (r = 0.430, p < 0.001), and CRP (r = 0.379, p < 0.001). FC levels exhibited a significantly better correlation with UCEIS than with MES (Meng’s z = − 2.457, p = 0.01). The FC cut-off level of 187.0 mg/kg indicated complete mucosal healing (MES = 0; UCEIS =0) with a sensitivity and specificity of 0.857 and 0.891, respectively (area under the curve, 0.883; 95% confidence interval, 0.772–1.000).

Conclusion

The FC level is significantly correlated with the clinical disease activity index, endoscopic indices, and serum inflammatory biomarkers in a Korean UC cohort. FC is highly predictive of complete mucosal healing in UC. UCEIS exhibits a stronger correlation with the FC level, as compared to MES. Thus, FC could be used as a reliable noninvasive indicator for evaluating disease activity and mucosal healing in UC.

Keywords

  • Calprotectin
  • Ulcerative colitis
  • Endoscopic score

Background

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by a disease course involving relapses and remissions [1]. Historically, clinical remission was the major treatment target for patients with UC. However, due to the unreliability and inaccuracy of symptoms indicating actual mucosal inflammation, there has been a paradigm shift towards therapeutically targeting more objective parameters such as mucosal healing (MH) in addition to other clinical endpoints [2–7]. In fact, MH is reportedly more strongly associated with both short-term and long-term outcomes in patients with UC [4, 7–9].

However, the use of repeated endoscopy to verify MH would be invasive, inconvenient, and expensive, and may present a risk of significant complications (i.e. colonic perforation). Therefore, noninvasive surrogate markers indicating endoscopic healing have been investigated to replace the repeated endoscopic procedures. Among these surrogate markers, fecal calprotectin (FC) has reportedly shown significant correlations with both clinical and endoscopic activity indices in patients with UC in several recent studies [10–14].

Among the endoscopic activity indices of UC, the Mayo endoscopic subscore (MES)—although not validated—is the most widely used index [15]. In addition, the ulcerative colitis endoscopic index of severity (UCEIS) has been recently developed and validated as a reliable endoscopic activity index in patients with UC [16, 17]. Although the correlation of FC levels with both MES and UCEIS has been previously evaluated by Theede et al. [14], a direct comparison between these correlations has not been described thus far. Moreover, only a few studies in Asia have evaluated the use of FC as a surrogate marker for disease activity in UC patients [18–23], and most of these reports were limited by their small sample size.

In the present study, we aimed to evaluate the diagnostic role of FC as a noninvasive marker for the disease activity of UC and to compare the correlations of FC with MES and UCEIS in a large Korean cohort.

Methods

Study population

Among patients with UC managed at Asan Medical Center (a tertiary care center in Seoul, Korea), a total of 181 consecutive patients who underwent FC measurements between April 2015 and September 2016 were enrolled in this study; all of these patients were of Korean descent. UC was diagnosed based on the current standard clinical, radiological, endoscopic, and histopathological criteria [24, 25]. A total of 181 fecal samples were collected from 181 UC patients. If repeated fecal samples were collected from a single patient, the first FC level measurement was used for the study. Detailed demographic and clinical information were retrieved from the electronic medical records and from the Asan IBD registry, which has been prospectively maintained since 1997 and has been previously described in detail [26, 27]. Collected data included birth date, sex, date of UC diagnosis, family history of IBD, smoking status, maximum disease extent, and medications. At our institute, all UC patients are instructed to record their bowel frequency and degree of rectal bleeding for 3 days before visiting the clinic to facilitate the measurement of the partial Mayo Score (pMS) [15]. During their visit, the pMS was calculated based on the patients’ records and physician’s global assessment using a computerized program incorporated into our electronic medical record system, and the value was recorded in the clinical note. When evaluating the correlation between FC levels and pMS, only the pMS values within 6 weeks of the FC measurement were used. The median time interval between FC and pMS evaluation was 2 days (interquartile range [IQR], 1-7 days).

Laboratory and endoscopic evaluation

The following laboratory parameters were recorded at the time of FC level measurement: complete blood cell count (XE-2100™, Sysmex, Kobe, Japan), including white blood cell count (normal range [NR], 4–10 × 103/μL), hemoglobin level (NR, 12–16 g/dL), hematocrit value (NR, 36–48%), and platelet count (NR, 150–350 × 103/μL); erythrocyte sedimentation rate (ESR; NR for men: 0–9 mm/h; NR for women: 0–20 mm/h; TEST 1, Alifax, Padova, Italy); and serum chemistry values (Cobas 8000 modular analyzer, Roche Diagnostics, Basel, Switzerland; AU5800 Beckman Coulter, Brea, CA), including C-reactive protein (CRP; NR, 0–0.6 mg/dL) and albumin (NR, 3.5–5.2 g/dL) levels. The time interval between the aforementioned laboratory tests and FC level measurement was within 2 months (median time interval, 0 day; IQR, 0-1 day).

The endoscopic images (full colonoscopic [75 cases] or flexible sigmoidoscopic [106 cases] images) obtained at the time of FC level measurement were reviewed by 2 board-certified endoscopic experts (B.D.Y. and S.W.H.) who were blinded to the clinical details, including FC levels and laboratory results. The time interval between the endoscopic procedure and FC level measurement was within 4 months (median time interval, 2 days; IQR, 0-15 days). All the endoscopic images were stored in the picture archiving and communication system (PACS) of Asan Medical Center. The 2 reviewers independently evaluated the endoscopic images and determined the MES and UCEIS [15, 16]. In case of a disagreement regarding the MES and UCEIS values between the 2 reviewers, a final score was recorded based on a consensus between the 2 reviewers. Prior to reviewing the 181 study cases, the endoscopic experts were trained using training set images of colonoscopy or flexible sigmoidoscopy from 50 other cases; during this training exercise, the reviewers independently determined the MES and UCEIS for 50 other cases, and consensus was sought regarding the scoring between the 2 reviewers to enhance the agreement in their scoring.

Analysis of the fecal calprotectin level

Patients were instructed to collect their fecal samples. Fecal samples were collected at the clinic or at home and were stored in a refrigerator (2–8 °C) when collected at home. The samples were sent to the department of laboratory medicine at Asan Medical Center within 1 day of collection for analysis. The laboratory personnel were blinded to the clinical data, laboratory values, and endoscopic findings of the patients. FC levels were measured using the Quantum Blue® Calprotectin rapid test (Bühlmann Laboratories AG, Schönenbuch, Switzerland), and high-range kit (measuring 100–1800 mg/kg) was used. All samples with FC levels exceeding the assay range of 1800 mg/kg were reanalyzed after dilution of the samples according to the manufacturer’s instructions for the exact measurement of the FC values. Cases with FC levels below the assay range (<100 mg/kg) were set as 100 mg/kg.

Statistical analysis

The continuous variables were reported as medians and interquartile ranges (IQR), whereas the categorical variables were reported as numbers and percentages. The inter-rater agreement of the endoscopic indices was analyzed using Cohen’s weighted Kappa coefficient. Correlation analysis was performed using Spearman’s rank correlation coefficient. The comparison between the coefficients of correlations of MES and UCEIS with the FC levels was conducted using Meng’s z coefficient [28]. The receiver operating characteristic (ROC) curves for the FC levels were assessed to predict the clinical and endoscopic activity indices. The comparison between the area under the ROC curve was analyzed using DeLong’s test [29]. A p value of <0.05 was considered statistically significant. All statistical analyses were performed using SPSS 21.0 for Windows (IBM SPSS Statistics, Ver. 21.0; IBM Co., Armonk, NY) and R V.3.4.0 (R Development Core Team).

Results

Patient characteristics

Among 181 study subjects, 107 (59.1%) were men, and the median age at diagnosis of UC was 35.8 years (IQR, 26.1–47.8 years; Table 1). The median age at FC level measurement was 40.5 years (IQR, 29.2–53.8 years) and the median disease duration prior to FC level measurement was 18.4 months (IQR, 1.9–59.5 months). The proportion of proctitis, left-sided colitis, and extensive colitis in the cohort was 18.2%, 26.0%, and 55.8%, respectively. Regarding severity of UC, 116 patients (64.1%) had moderate or severe disease activity. With regard to the history of UC medication use, 154 (85.1%), 116 (64.1%), and 124 (68.5%) patients were administered oral 5-aminosalicylic acids, topical 5-aminosalicylic acids, and systemic corticosteroids, respectively (Table 1). Fifty-eight (32.0%) and 30 (16.6%) patients were treated with thiopurines and anti-tumor necrosis factor-α agents, respectively (Table 1).
Table 1

Demographic and clinical characteristics of the study subjects

Variables

UC (N = 181)

Sex

 Male

107 (59.1%)

Age at UC diagnosis (years), median (IQR)

35.8 (26.1–47.8)

Age at FC level measurement (years), median (IQR)

40.5 (29.2–53.8)

Disease duration before FC level measurement (months), median (IQR)

18.4 (1.9–59.5)

Maximum extent of UC

 Proctitis

33 (18.2%)

 Left-sided colitis

47 (26.0%)

 Extensive colitis

101 (55.8%)

Disease severity of UC

 Clinical remission (Mayo score 0-2)

17 (9.4%)

 Mild activity (Mayo score 3-5)

48 (26.5%)

 Moderate activity (Mayo score 6-10)

98 (54.1%)

 Severe activity (Mayo score 11-12)

18 (10.0%)

Smoking status at UC diagnosis

 Never smoker

100 (55.2%)

 Former smoker

47 (26.0%)

 Current smoker

34 (18.8%)

Family history of IBD

 No family history

171 (94.5%)

 First-degree relative

9 (5.0%)

 Second-degree relative

1 (0.5%)

History of medication use at FC level measurement

 Oral 5-ASA

154 (85.1%)

 Topical 5-ASA

116 (64.1%)

 Topical steroids

32 (17.7%)

 Systemic corticosteroids

124 (68.5%)

 Thiopurines

58 (32.0%)

 Cyclosporine

4 (2.2%)

 Anti-TNF agents

30 (16.6%)

FC level (mg/kg), median (IQR)

1518.0 (360.0–4205.0)

Hematocrit value (%), median (IQR)

37.7 (32.8–42.0)

Serum albumin level (g/dL), median (IQR)

3.7 (2.9–4.0)

Erythrocyte sedimentation rate (mm/h), median (IQR)

26.0 (11.5–44.5)

White blood cell count (×103 /uL), median (IQR)

7.1 (5.6–9.5)

Platelet count (×103 /uL), median (IQR)

300.0 (242.0–379.0)

C-reactive protein level (mg/L), median (IQR)

0.41 (0.10–2.37)

Partial Mayo score, median (IQR)

5 (2–6.5)

Mayo endoscopic subscore, median (IQR)

3 (2–3)

Mayo score, median (IQR)

6 (3–8)

UCEIS, median (IQR)

4 (3–6)

UC ulcerative colitis, FC fecal calprotectin, IBD inflammatory bowel disease, TNF tumor necrosis factor, N Number, IQR interquartile range, ASA aminosalicylic acid, UCEIS ulcerative colitis endoscopic index of severity

The median FC level was 1518.0 mg/kg (IQR, 360.0–4205.0 mg/kg), whereas the median pMS, MES, and UCEIS values were 5 (IQR, 2–6.5), 3 (IQR, 2–3), and 4 (IQR, 3–6), respectively (Table 1).

Correlation of the fecal calprotectin level with biochemical markers

Among the biochemical markers, FC levels exhibited significant correlations with the CRP (r = 0.379, p < 0.001) and serum albumin (r = − 0.426, p < 0.001) levels (Fig. 1). The other laboratory values including white blood cell count (r = 0.231, p = 0.001), hematocrit value (r = − 0.238, p = 0.001), platelet count (r = 0.313, p < 0.001), and ESR (r = 0.249, p < 0.001) exhibited weaker correlations with the FC levels, as compared to both the CRP and serum albumin levels (Fig. 1).
Fig. 1
Fig. 1

Correlation between fecal calprotectin levels and a) serum albumin levels (r = −0.426, p < 0.001); b) CRP levels (r = 0.379, p < 0.001); c) platelet counts (r = 0.313, p < 0.001); d) partial Mayo Score (r = 0.428, p < 0.001); e) Mayo endoscopic subscore (r = 0.304, p < 0.001); and f) UCEIS (r = 0.430, p < 0.001). r Spearman’s correlation coefficient, CRP C-reactive protein, UCEIS ulcerative colitis endoscopic index of severity

Correlation of the fecal calprotectin level with the disease activity index and endoscopic indices

The Cohen’s weighted Kappa coefficient of inter-rater agreement for MES and UCEIS were 0.78 (95% confidence interval [CI], 0.71–0.85) and 0.62 (95% CI, 0.56–0.69), respectively (Table 2). The Cohen’s weighted Kappa coefficient of the ‘vascular’, ‘bleeding’, and ‘erosions and ulcers’ items of the UCEIS were 0.69 (95% CI, 0.56–0.69), 0.40 (95% CI, 0.31–0.49), and 0.74 (95% CI, 0.67–0.81), respectively. The UCEIS and MES showed a strong correlation with each other (r = 0.876, p < 0.001). The FC levels exhibited significant correlations with the pMS (Spearman correlation coefficient r = 0.428, p < 0.001), MES (r = 0.304, p < 0.001), and UCEIS (r = 0.430, p < 0.001) (Fig. 1). When comparing the degree of correlation between the FC levels and endoscopic indices, UCEIS showed a better correlation with the FC levels, as compared to MES (Meng’s z = − 2.457, p = 0.01).
Table 2

Inter-rater agreement of the endoscopic indices in the 181 study subjects

Variables

Weighted Kappaa

95% CI

Mayo endoscopic subscore

0.78

0.71–0.85

UCEIS

0.62

0.56–0.69

 Vascular

0.69

0.57–0.80

 Bleeding

0.40

0.31–0.49

 Erosions and ulcers

0.74

0.67–0.81

aWeighted kappa (all levels disagreement between raters are weighted equally)

CI confidence interval, UCEIS ulcerative colitis endoscopic index of severity

Receiver operating characteristics curve analysis

ROC curve analysis indicated a FC cut-off level of 187.0 mg/kg (area under the curve [AUC], 0.883; 95% CI, 0.772–1.000) for predicting complete MH defined as MES value of 0 (Table 3). ROC analysis revealed the equal FC cut-off level of 187.0 mg/kg (AUC, 0.883; 95% CI, 0.772–1.000) for predicting complete MH defined as a UCEIS value of 0 (Table 3). The sensitivity and specificity of the cut-off value of 187.0 mg/kg for complete MH were 0.857 and 0.891, respectively (Table 3).
Table 3

Cut-off FC levels for discriminating clinical remission and mucosal healing

 

Cut-off FC level (mg/kg)

AUC (95% CI)

p value

Sensitivity

Specificity

pMS = 0

1272

0.748 (0.616–0.880)

<0.001

0.857

0.599

pMS = 0–2

2211

0.772 (0.701–0.842)

<0.001

0.875

0.592

MES = 0

187

0.883 (0.772–1.000)

<0.001

0.857

0.891

UCEIS = 0

187

0.883 (0.772–1.000)

<0.001

0.857

0.891

pMS partial Mayo score, MES Mayo endoscopic subscore, UCEIS ulcerative colitis endoscopic index of severity, FC fecal calprotectin, AUC area under curve, CI confidence interval

ROC curve analysis showed much higher FC cut-off levels of 1272.0 mg/kg (AUC, 0.748; 95% CI, 0.616–0.880) for predicting complete clinical remission (pMS = 0) and 2211.0 mg/kg (AUC, 0.772; 95% CI, 0.701–0.842) for predicting near-complete clinical remission (pMS = 0–2) (Table 3). The sensitivity and specificity of both cut-off values of 1272.0 mg/kg (pMS = 0) and 2211.0 mg/kg (pMS = 0–2) were 0.857 and 0.599, and 0.875 and 0.592, respectively (Table 3). The AUC of the FC level for predicting near-complete MH defined as MES = 0–1 was 0.686 (95% CI, 0.578–0.793; Fig. 2a). In contrast, the AUC values of the FC level for predicting UCEIS = 0, 0–1, 0–2, and 0–3 were 0.883 (95% CI, 0.772–1.000), 0.678 (95% CI, 0.567–0.788), 0.725 (95% CI, 0.640–0.809), and 0.730 (95% CI, 0.653–0.806), respectively. When comparing the AUC of FC levels for predicting MES = 0 and MES = 0-1, the DeLong’s test showed significant difference (Z = −2.001, p = 0.046) (Fig. 2a). Similarly, when comparing the AUC of FC levels for predicting UCEIS = 0 and UCEIS = 0-1, the DeLong’s test showed significant difference (Z = −2.064, p = 0.04) (Fig. 2b).
Fig. 2
Fig. 2

ROC curve analysis showing the AUC of the FC level and comparison between the AUCs (DeLong’s test) of the FC level a) for predicting MES = 0 and MES = 0-1; b) for predicting UCEIS = 0 and UCEIS = 0-1. FC fecal calprotectin, ROC receiver operating characteristics, AUC area under curve, MES Mayo endoscopic subscore, UCEIS ulcerative colitis endoscopic index of severity, CI confidence interval, Z coefficient of DeLong’s test

After combining additional biochemical variables to FC, the AUC of FC + CRP for predicting MES = 0 and MES = 0–1 were 0.874 and 0.795, respectively, and the AUC of FC + CRP + serum albumin for predicting MES = 0 and MES = 0–1 were 0.878 and 0.837, respectively (Fig. 3). A similar trend was observed for UCEIS. The AUC of FC + CRP for predicting UCEIS = 0 and UCEIS = 0-1 were 0.874 and 0.789, respectively, whereas the AUC of FC + CRP + serum albumin for predicting UCEIS = 0 and UCEIS = 0-1 were 0.878 and 0.836, respectively (Fig. 3).
Fig. 3
Fig. 3

ROC curve analysis showing the AUC of the FC level in combination of biochemical variables for predicting a) MES = 0; b) UCEIS = 0; c) MES = 0-1; d) UCEIS = 0–1. FC fecal calprotectin, ROC receiver operating characteristics, AUC area under curve, MES Mayo endoscopic subscore, UCEIS ulcerative colitis endoscopic index of severity

Discussion

In the present study, we evaluated the correlation of the FC levels with the 2 endoscopic severity indices commonly used in patients with UC. To our knowledge, this is the first study to directly compare between the correlation coefficients of MES and UCEIS with FC levels.

Our study showed a significant correlation of the FC level with both the CRP and serum albumin levels. Because both FC and CRP are representative inflammatory biomarkers used in monitoring disease activity in patients with IBD, they were expected to exhibit a good correlation, consistent with previous studies [19, 22]. However, no previous study has indicated a significant correlation between the FC level and the serum albumin level. Although protein loss from the gut and malnutrition may influence the serum albumin level, the albumin level is also known to decrease in active disease and to be negatively correlated with UC disease activity; this could explain the negative correlation between the serum albumin and FC levels [30, 31]. Moreover, the significant correlation between FC and serum albumin in our study might reflect the high proportion of moderate to severe disease activity in our cohort. In addition, when considering the clinical activity of UC, our study showed a significant correlation between FC and pMS, consistent with the results of the study by Theede et al. [14].

With regard to the endoscopic activity indices, both MES and UCEIS exhibited significant correlations with the FC level in our study, consistent with the observations from previous studies [11, 14, 18–20, 22, 23, 32–34]. Only one previous study by Theede et al. evaluated the correlation of FC levels with both MES and UCEIS [14]. However, the researchers did not directly compare the correlation coefficients of the FC levels with MES and UCEIS. To further determine the significance of the difference between the correlation coefficients of the 2 endoscopic indices with the FC level, we assessed Meng’s z score in the present study [28]. Based on our results, FC levels were better correlated with UCEIS than with MES. However, our results should be validated in a larger number of subjects and in different ethnic groups.

Another strength of our study was the use of endoscopic scores graded by 2 certified expert endoscopists. To increase the inter-rater agreement on scoring, initial training with 50 other cases was performed. As a result, both MES and UCEIS showed substantial inter-rater agreement (weighted Kappa [95% CI] of 0.78 [0.71–0.85] and 0.62 [0.56–0.69], respectively), which was comparable to the inter-rater agreement of UCEIS (weighted Kappa [95% CI]: 0.5 [0.49–0.52]) determined by Travis et al. [17, 35]. The ‘bleeding’ item of the UCEIS had the lowest weighted Kappa coefficient, consistent with that reported by Travis et al. [17, 35]. Travis et al., explained that this may be due to the misinterpretation of the descriptions and the confusion of spontaneous bleeding with contact bleeding [17]. Given the fact that the majority of our study patients had moderate to severe disease activities, the difficulties in differentiation between spontaneous bleeding and contact bleeding especially in this retrospective setting might have contributed even more to the low inter-rater agreement of the ‘bleeding’ item. Despite the presence of significant correlations between UCEIS and MES, UCEIS tended to have a weaker inter-rater agreement as compared to MES, which may possibly be due to the larger number of items used for scoring UCEIS. Nevertheless, further studies are warranted for the comparison of MES and UCEIS.

The cut-off FC level for MH defined as MES = 0 and UCEIS = 0 was equal (187.0 mg/kg). This level is similar to the cut-off level of 192 mg/kg for MH defined as MES = 0 and for MH defined as UCEIS = 0 in the study by Theede et al. [14], and 200 mg/kg for MH defined as MES = 0 in the study by Takashima et al. [20]. Therefore, the cut-off FC level for the strict definition of MH appears to be similar across ethnicities. However, in the present study, the cut-off FC level for complete clinical remission defined as pMS = 0 was relatively high (1272.0 mg/kg), as compared to the cut-off value of 192 mg/kg reported in the study by Theede et al. [14]. This discrepancy may be related to the subjectiveness of the pMS, which is estimated based on bowel frequency, presence of rectal bleeding, and the physician’s global assessment; such bias may reduce the reliability of pMS as a marker of actual mucosal inflammation.

Based on the ROC curve analyses, the AUC of FC for predicting complete MH defined as MES = 0 and UCEIS = 0 had the greatest power of predictability and was comparable with the results of Theede et al. [14]. In comparison between AUC levels, FC had a better predictability of complete MH (MES = 0, UCEIS = 0) rather than near-complete MH (MES = 0-1, UCEIS = 0-1) (DeLong’s test Z = −2.001 [p = 0.046], Z = −2.064 [p = 0.04]). In addition, AUC could be increased when the FC level was combined with other biochemical markers for predicting near-complete MH (MES = 0-1, UCEIS = 0-1), consistent with the study by Lin et al. [19]. However, AUC could not be increased with the combination of biochemical markers for predicting complete MH (MES = 0, UCEIS = 0). Based on our ROC curve analyses, we could conclude that FC significantly predicts complete MH in UC patients. Although other biochemical markers in combination to FC enhanced the predictability of near-complete MH (MES = 0-1 and UCEIS = 0-1), combination of other biochemical markers to FC did not seem to affect the predictability of complete MH. Future studies on different patient population should further explore the predictability of FC and biochemical markers for predicting MH in UC patients.

The present study had certain limitations of note. First, the analysis was retrospective. Yet, our IBD registry was prospectively maintained and the pMS was also prospectively recorded at each patient visit. Second, despite the presence of statistical significance, the correlation coefficients between the FC level and clinical activity index and endoscopic activity indices appeared to be lower than the values reported in other studies. This can be explained by the variable intervals between the time of FC level measurement and clinical and endoscopic index scoring, which is a major limitation of a retrospective study. For instance, patients with shorter intervals between FC level measurement and endoscopy showed better correlation coefficients (for interval ≤ 14 days: r = 0.392, p < 0.001; for interval > 14 days: r = 0.199, p = 0.180). The differences in the FC measurement modalities and study subjects might also have contributed to the different results between the present results and those of previous studies. In addition, the difference between the modalities of endoscopy (full colonoscopy and flexible sigmoidoscopy) might have also contributed to this issue. Third, the FC levels in the present study were relatively higher than those in other studies. The median FC level in our study was 1518.0 mg/kg (IQR, 360.0–4205.0 mg/kg), which was slightly higher than the median FC level (1020.0 mg/kg; IQR, 601.5–1617.5 mg/kg) in the study by Ho et al. in an acute severe UC setting [36]. This may be explained by the selection bias due to the higher severity of UC patients referred to our hospital, which is a tertiary referral center with the largest IBD center in Korea. Although there was no recommended method to exactly measure FC levels below 100 mg/kg, nevertheless, we decided to include cases with the FC levels <100 mg/kg (FC <100 mg/kg were set as 100 mg/kg) to minimize additional selection bias. Finally, the correlation between the FC level and histologic inflammation was not evaluated in our study.

Conclusions

In conclusion, FC levels exhibit significant correlations with the clinical activity index, endoscopic activity indices, and other serum inflammatory biomarkers in Korean patients with UC. FC is highly predictive of complete mucosal healing in UC patients. In particular, UCEIS shows a better correlation with the FC level as compared to the MES. Thus, FC could be used as a reliable noninvasive indicator for evaluating disease activity and mucosal healing in patients with UC.

Notes

Abbreviations

AUC: 

Area under the curve

CI: 

Confidence interval

CRP: 

C-reactive protein

ESR: 

Erythrocyte sedimentation rate

FC: 

Fecal calprotectin

IBD: 

Inflammatory bowel disease

IQR: 

Interquartile range

MES: 

Mayo endoscopic subscore

MH: 

Mucosal healing

NR: 

Normal range

pMS: 

Partial Mayo score

ROC: 

Receiver operating characteristics

UC: 

Ulcerative colitis

UCEIS: 

Ulcerative colitis endoscopic index of severity

Declarations

Acknowledgements

None.

Funding

None.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

SHL participated in collecting and analyzing the data, and drafted the manuscript. MJK participated in statistical analysis of the data. KJC, EMS participated in editing the manuscript. SHP, DHY, KJK, JSB, SJM, SKY participated in revising the manuscript. SWH participated in endoscopic grading. BDY participated in endoscopic grading, designed the study, and revised the manuscript critically. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board (IRB) of Asan Medical Center (IRB number: 2016-1122). Informed consent was waived by the institutional review board of Asan Medical Center due to the retrospective design of the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea
(2)
Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea
(3)
Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea

References

  1. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107(1):3–11.View ArticlePubMedGoogle Scholar
  2. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–201.View ArticlePubMedGoogle Scholar
  3. Frøslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–22.Google Scholar
  4. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16(2):338–46.View ArticlePubMedGoogle Scholar
  5. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB, et al. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5(5):477–83.View ArticlePubMedGoogle Scholar
  6. Sandborn WJ, Panés J J, Zhang H, Yu D, Niezychowski W, Su C. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology. 2016;150(1):96–102.Google Scholar
  7. Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(9):1245–55. e1248View ArticlePubMedGoogle Scholar
  8. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–38.View ArticlePubMedGoogle Scholar
  9. Wei SC. Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease? Intestinal Res. 2016;14(4):293–4.View ArticleGoogle Scholar
  10. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–24.View ArticlePubMedGoogle Scholar
  11. Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O,  Høie O, Rydning A, Vatn MH, Group IIS. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol. 2011;46(9):1081–91.Google Scholar
  12. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332–41.View ArticlePubMedGoogle Scholar
  13. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15(12):1851–8.View ArticlePubMedGoogle Scholar
  14. Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(11):1929–36. e1921.Google Scholar
  15. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9.View ArticlePubMedGoogle Scholar
  16. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS). Gut. 2012;61(4):535–42.Google Scholar
  17. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145(5):987–95.View ArticlePubMedGoogle Scholar
  18. Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, et al. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol. 2016;16:47.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Lin WC, Wong JM, Tung CC, Lin CP, Chou JW, Wang HY, Shieh MJ, Chang CH, Liu HH, Wei SC, et al. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol. 2015;21(48):13566–73.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110(6):873–80.Google Scholar
  21. Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14(1):53–7.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, Sato Y, Kasuga N, Nakamura T. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci. 2004;49(9):1438–43.View ArticlePubMedGoogle Scholar
  23. Samant H, Desai D, Abraham P, Joshi A, Gupta T, Dherai A, Ashavaid T. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease. Indian J Gastroenterol. 2015;34(6):431–5.View ArticlePubMedGoogle Scholar
  24. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6. discussion 16-19View ArticlePubMedGoogle Scholar
  25. Yang SK, Hong WS, Min YI, Kim HY, Yoo JY, Rhee PL, Rhee JC, Chang DK, Song IS, Jung SA, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol. 2000;15(9):1037–42.View ArticlePubMedGoogle Scholar
  26. Park SH, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, et al. Long-term prognosis of Crohn's disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Inflamm Bowel Dis. 2014;20(3):488–94.Google Scholar
  27. Lee HS, Park SH, Yang SK, Lee J, Soh JS, Lee S, Bae JH, Lee HJ, Yang DH, Kim KJ, et al. Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea. J Crohns Colitis. 2015;9(2):147–55.View ArticlePubMedGoogle Scholar
  28. Meng X-l, Rosenthal R, Rubin DB. Comparing correlated correlation coefficients. Psychol Bull. 1992;111(1):172–5.Google Scholar
  29. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.View ArticlePubMedGoogle Scholar
  30. Azzolini F, Pagnini C, Camellini L, Scarcelli A, Merighi A, Primerano AM, Bertani A, Antonioli A, Manenti F, Rigo GP. Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis. Dig Dis Sci. 2005;50(2):246–51.View ArticlePubMedGoogle Scholar
  31. Bendixen G, Goltermann N, Jarnum S, Jensen KB, Weeke B, Westergaard H. Immunoglobulin and albumin turnover in ulcerative colitis. Scand J Gastroenterol. 1970;5(5):433–41.PubMedGoogle Scholar
  32. D'Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Color Dis. 2007;22(4):429–37.Google Scholar
  33. Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58(2):176–80.Google Scholar
  34. Taghvaei T, Maleki I, Nagshvar F, Fakheri H, Hosseini V, Valizadeh SM, Neishaboori H. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med. 2015;10(3):321–8.View ArticlePubMedGoogle Scholar
  35. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, et al. The impact of clinical information on the assessment of endoscopic activity: characteristics of the ulcerative colitis endoscopic index of severity [UCEIS]. J Crohns Colitis. 2015;9(8):607–16.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104(3):673–8.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement

BMC Gastroenterology

ISSN: 1471-230X

Contact us